Financial health
- Operating income covered interest expense -260.4× in the latest year.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$178M | — | — | — | — | $92700 |
| 2024 | — | -$88M | — | — | -$11M | — | $220467 |
| 2023 | — | -$40M | — | — | -$12M | — | $2M |
| 2022 | — | -$113M | — | — | -$16M | — | $9M |
| 2021 | — | -$27M | — | — | -$21M | — | $21M |
| 2020 | — | -$11M | — | — | -$11M | — | $9M |
| 2019 | — | -$18M | — | — | -$9M | — | $12M |
| 2018 | — | -$6M | — | — | -$4M | — | $16M |
| 2017 | — | -$2M | — | — | — | — | $4M |
| 2016 | — | -$2M | — | — | — | $102882 | $23368 |
| 2014 | — | -$2M | — | — | — | $99951 | $3M |
| 2013 | $32768 | -$2M | -233.6% | -5306.8% | — | $728001 | $18794 |
| 2013 | — | -$95587 | — | — | — | — | — |
| 2013 | — | -$79181 | — | — | — | — | — |
| 2013 | — | -$37589 | — | — | — | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $20942 | -$3M | 100.0% | -7054.1% | -$1M | — | $3M |
| Dec '25 | — | -$2M | — | — | — | — | $491645 |
| Sep '25 | — | $3M | — | — | — | — | $624808 |
| Jun '25 | — | -$127M | — | — | — | — | $92700 |
| Mar '25 | — | $189176 | — | — | — | — | $923002 |
| Dec '24 | — | -$7M | — | — | — | — | $311764 |
| Sep '24 | — | -$44M | — | — | — | — | $220571 |
| Jun '24 | — | -$16M | — | — | -$2M | — | $220467 |
| Mar '24 | — | -$59M | — | — | -$3M | — | $312697 |
| Dec '23 | — | -$5M | — | — | — | — | $243980 |
| Sep '23 | — | -$9M | — | — | — | — | $523474 |
| Jun '23 | — | -$23M | — | — | -$2M | — | $2M |
| Mar '23 | — | -$4M | — | — | -$3M | — | $3M |
| Dec '22 | — | -$4M | — | — | — | — | $4M |
| Sep '22 | — | -$8M | — | — | — | — | $8M |
| Jun '22 | — | -$90M | — | — | -$3M | — | $9M |
| Mar '22 | — | -$6M | — | — | -$3M | — | $11M |
| Dec '21 | — | -$7M | — | — | -$5M | — | $14M |
| Sep '21 | — | -$10M | — | — | -$5M | — | $15M |
| Jun '21 | — | -$17M | — | — | -$13M | — | $21M |
See the revenue and net-income charts above for Lunai Bioworks Inc.'s multi-year trend.
As of FY2025, Lunai Bioworks Inc. reported — of total debt against $92700 of cash; operating income covered interest expense -260.4×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.